Quantcast

Latest Raptor Pharmaceuticals Corp. Stories

2009-10-01 15:05:00

SAN FRANCISCO, Oct. 1 /PRNewswire-FirstCall/ -- Merriman Curhan Ford Group, Inc. (Nasdaq: MERR) acted as a financial advisor to TorreyPines Therapeutics, Inc. in the recent merger with Raptor Pharmaceuticals Corp. (Logo: http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO) The combined company is named "Raptor Pharmaceutical Corp." and commenced trading on September 30, 2009 on the NASDAQ Capital Market under the ticker symbol "RPTP." Further details on the merger can be found at...

2009-09-30 05:30:00

NOVATO, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) announced today the completion of their merger. The combined company is named "Raptor Pharmaceutical Corp." and will commence trading on September 30, 2009 on the NASDAQ Capital Market under the ticker symbol "RPTP." Pursuant to NASDAQ's regulations, for the first 20 trading days the ticker symbol will be...

2009-09-28 15:05:00

NOVATO, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that its stockholders approved the proposals to complete the proposed merger with TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) at its annual meeting of stockholders held on Monday, September 28, 2009. Concurrently, at the annual meeting of its stockholders, TorreyPines stockholders approved all of the proposals related to...

2009-09-02 08:00:00

LOS ANGELES, Sept. 2 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceuticals Corp. and raised its twelve month target price to $1.53. "Raptor is at an inflection point in that they are soon to be a NASDAQ listed company as a result of their pending merger with TorreyPines (expected to close in Q4 2009) and they will potentially have their cystinosis drug on the market in the first half of 2011. The fact that Raptor is potentially 18 months away...

2009-08-25 05:30:00

NOVATO, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has raised an aggregate $5 million of gross proceeds through a private placement of units ("August 2009 Private Placement") and through the exercise of warrants (the "Warrant Exchange") originally issued in connection with its May/June 2008 private placement. The August 2009 Private Placement resulted in gross proceeds to Raptor of...

2009-07-30 16:15:00

LA JOLLA, Calif., July 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced today that it has cancelled its Special Meeting of Stockholders, scheduled for today at 9:00 a.m., local time. The purpose of the meeting was for stockholder to vote upon a proposal to approve the liquidation and dissolution of TPTX. Given the recent entry in an Agreement and Plan of Merger by and between TPTX and Raptor Pharmaceuticals Corp., TPTX's Board approved cancelling the meeting in...

2009-07-28 05:45:00

Nasdaq-Listed Biopharmaceutical Company Focusing on Improved Drug Targeting and Reformulation of Existing Therapeutic Compounds to Benefit Underserved Patient Populations NOVATO, Calif. and LA JOLLA, Calif., July 28 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX), today announced that they have entered into a definitive merger agreement. Upon closing, the merger...

2009-07-16 05:00:00

NOVATO, Calif., July 16 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that Patrice P. Rioux, M.D., Ph.D., Raptor's Chief Medical Officer, will present an update on the Company's ongoing Phase 2b study of delayed-release cysteamine bitartrate ("DR Cysteamine") for the potential treatment of cystinosis, and its plans for further clinical development of the product candidate, at the Cystinosis Research Network...

2009-06-09 05:30:00

Roche to fund evaluation of Raptor's proprietary NeuroTrans(TM) technology NOVATO, Calif., June 9 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has entered a collaboration and licensing agreement with Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) to evaluate therapeutic delivery across the blood-brain barrier, ("BBB") starting with Raptor's proprietary NeuroTrans(TM) BBB transporter platform. Under terms of...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related